Skip to main content

Day: December 27, 2023

VERB’s CEO Addresses Stockholders in Year-End Letter

LOS ALAMITOS, Calif. and LAS VEGAS, Dec. 27, 2023 (GLOBE NEWSWIRE) — Verb Technology Company, Inc. (Nasdaq: VERB) (“VERB” or the “Company”), the company behind MARKET.live, the innovative multi-vendor, multi-presenter livestream social shopping platform, announces today that VERB CEO Rory J. Cutaia has issued a year-end letter to its stockholders, published in its entirety below. Dear Verb Stockholders As the year draws to a close, I wanted to take this opportunity to thank you all for your continuing support, to reflect on the events of the past year, including the enormous challenges we faced together, as well as the accomplishments, of which there have been many, and share a glimpse of our exciting path forward in 2024 and beyond. 2023 began with our Board and senior management team already engrossed...

Continue reading

Ranchero Announces Proposed Disposition of the Santa Daniela Property for a Total Consideration of Up to US$5.05m

VANCOUVER, British Columbia, Dec. 27, 2023 (GLOBE NEWSWIRE) — Ranchero Gold Corp. (“Ranchero” or the “Company”) (TSX.V:RNCH) is pleased to announce that its wholly-owned subsidiary Minera y Metalurgia Paika, S.A. de C.V. (“Paika”) has entered into a letter of intent dated December 22, 2023 (the “LOI”) with Minas de Oro Nacional, S.A. de C.V. (“Minas de Oro”), a wholly-owned subsidiary of Alamos Gold Inc. (TSX:AGI), for the proposed sale of Paika’s interest in four mineral licenses (the “Licenses”) comprising an area of 5,390 hectares, which represents approximately 24% of the surface area of the Company’s Santa Daniela mineral property located in Sonora, Mexico, in consideration for the cash payment of US$2,550,000 (the “Cash Payment”) and a conditional cash payment of US$2,500,000 (the “Disposition”). An initial tranche of the...

Continue reading

Amniotic Membrane Market Size Worth USD 10.53 Billion in 2032 | Emergen Research

Increasing number of accidents, trauma cases, target patient population, and stem cell research, rising awareness about benefits of AM benefits and government funding and AM transplantation, and advancements in regeneration medicine are key factors driving amniotic membrane market revenue growth. Vancouver, Dec. 27, 2023 (GLOBE NEWSWIRE) — The global Amniotic Membrane (AM) market size was USD 3.20 Billion in 2022 and is expected to register a rapid revenue CAGR of 12.6% during the forecast period. The market is driven by several key factors, including the increasing incidence of accidents and trauma cases, a growing target patient population, advancements in stem cell research, and rising awareness about the benefits of AM in burns treatment. Amniotic membrane, a thin tissue layer with antiviral, antimicrobial, and anti-inflammatory...

Continue reading

Crazy Woman Creek Bancorp Reports Earnings for Fiscal Year 2023

BUFFALO, Wyo., Dec. 27, 2023 (GLOBE NEWSWIRE) — We continue to build our franchise as Crazy Woman Creek Bancorp (OTCPink: CRZY) and Buffalo Federal Bank, known as The Banks of Buffalo, Sheridan, Gillette and BFSB Mortgage of Evanston. Headquartered in Buffalo, Wyoming, our bank remains a vital business and community partner since founding in 1936. We take great pride in meeting our customers’ banking needs with a passion for local decision-making and personal involvement in our communities. Our vision remains to be the premier community bank serving the needs of individuals, families and businesses throughout North-Central Wyoming. Given our commitment to shareholders, along with balancing anticipated economic and/or regulatory requirements, we have elected to retain our cash dividend traditionally paid in January. The cash retention...

Continue reading

Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise

CHESTERBROOK, Pa., Dec. 27, 2023 (GLOBE NEWSWIRE) — Trevena Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has entered into definitive agreements for the issuance and sale of 2,779,906 shares of common stock (or pre-funded warrants in lieu thereof) of Trevena and warrants to purchase up to an aggregate of 2,779,906 shares of common stock of Trevena, at a purchase price of $0.70 per share (or pre-funded warrant in lieu thereof) and associated warrant in a private placement, for expected gross proceeds to the Company of approximately $1.946 million (the “private placement”). The Company has also entered into a definitive agreement for the immediate exercise...

Continue reading

Wrap Technologies, Inc. Announces Largest BolaWrap Order in Company History

TEMPE, Ariz., Dec. 27, 2023 (GLOBE NEWSWIRE) — Wrap Technologies, Inc. (Nasdaq: WRAP) (“Wrap” or the “Company”), a global leader in innovative public safety and private security solutions, proudly announces a landmark milestone in its history, having received a $4.9 million BolaWrap order for the fourth quarter of 2023. This deal represents the largest order in Company history and signifies the first step in what the Company anticipates will be a large global deployment opportunity for WRAP’s solution set in 2024. Today’s news demonstrates the potential demand for WRAP’s groundbreaking BolaWrap device, a non-lethal restraint solution designed to assist law enforcement in safely apprehending individuals without causing harm. The order, placed by a Company distributor, is a testament to the increasing recognition of BolaWrap’s...

Continue reading

Richtech Robotics Announces Closing of Underwriters’ Over-Allotment Option in Connection With Its Initial Public Offering

LAS VEGAS, Dec. 27, 2023 (GLOBE NEWSWIRE) — Richtech Robotics Inc. (Nasdaq: RR) (“Richtech Robotics” or the “Company”), a Nevada company and a provider of AI-driven service robots for the hospitality and healthcare industries, today announced that it issued an additional 42,563 shares of the Company’s Class B common stock pursuant to partial exercise of the underwriters’ over-allotment option in connection with the Company’s initial public offering at $5.00 per share, resulting in additional gross proceeds of $212,815. Total proceeds of the Company’s initial public offering, including the exercise of the over-allotment option, were $10,712,815. The Company’s Class B common stock is listed on the Nasdaq Capital Market under the ticker symbol “RR.” R. F. Lafferty & Co., Inc. acted as sole book-running manager for the offering....

Continue reading

Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108

Company to retain economic interest in biotherapeutic asset while removing cash burn from development and commercialization costs REDWOOD CITY, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into a purchase agreement with Nestlé Health Science, a globally recognized leader in the field of nutritional science, for CDX-7108, an investigational therapy for the potential treatment of exocrine pancreatic insufficiency (EPI). Under the terms of the agreement, Codexis will receive up to $45M in potential milestone payments, including a $5M upfront payment, as well as single-digit net-sales-based royalties. Codexis will receive up to an additional $5M if Nestlé Health Science exercises an option to purchase two additional early-stage enzymes being...

Continue reading

Information Release Calendar for 2024

Šiaulių Bankas shall publish the information to investors in 2024 in accordance with the following calendar:29/02/2024 Interim information for 12 months of 202329/02/2024 Investor Conference Webinar of introducing the financial results for the 202308/03/2024 Notice on convocation of the Ordinary General Shareholder Meeting (GSM), draft resolutions for the convened GSM29/03/2024 Ordinary General Shareholder Meeting (GSM), Resolutions of the GSM29/03/2024 Audited annual information for 202329/04/2024 Interim information for 3 months of 202429/04/2024 Investor Conference Webinar of introducing the financial results for the 1 quarter of 202429/07/2024 Interim information for 6 months of 202429/07/2024 Investor Conference Webinar of introducing...

Continue reading

Trinity Biotech Announces It Has Begun Shipments of Its New HIV Screening Test, TrinScreen HIV to Kenya

DUBLIN, Ireland, Dec. 27, 2023 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announces it has begun commercial shipments to Kenya of its new rapid HIV screening test, TrinScreen HIV. The Kenyan HIV screening programme is one of the largest in Africa, with an estimated 10 million HIV screening tests performed annually. The Company has begun commercial shipments as part of the initial purchase order the Company received for 2.5 million tests, with further shipments under that purchase order scheduled for early 2024. Trinity understands that the Kenyan Ministry of Health has received commitments from all relevant sponsors (including Global Fund and USAID) to fund the procurement from the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.